<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067140</url>
  </required_header>
  <id_info>
    <org_study_id>ARV-766-mCRPC-101</org_study_id>
    <nct_id>NCT05067140</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arvinas Androgen Receptor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arvinas Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of ARV-766 in men with metastatic&#xD;
      castration-resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate ARV-766 given once or twice daily to cohorts of patients in&#xD;
      escalating doses. Each dose level will have safety assessed and if found safe and tolerable,&#xD;
      the next cohort of patients will be enrolled at a higher dose level. Increasing dose levels&#xD;
      will be evaluated until the highest safe dose is identified. Patients treated at lower doses&#xD;
      may increase to the next higher dose level once it is determined to be safe, provided they&#xD;
      have been on their current dose for 28 or more days and have no major side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">June 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subsequent dose level is determined by the Cohort Review Committee after the initial starting dose cohort and each subsequent dose cohort completes the first 28 days of treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities of ARV-766</measure>
    <time_frame>28 Days</time_frame>
    <description>First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-766</measure>
    <time_frame>28 Days</time_frame>
    <description>Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-766</measure>
    <time_frame>28 Days</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), and timing.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>ARV-766</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet(s), once or twice daily in 28 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARV-766</intervention_name>
    <description>Daily dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.</description>
    <arm_group_label>ARV-766</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological, pathological, or cytological confirmed diagnosis of adenocarcinoma of&#xD;
             the prostate.&#xD;
&#xD;
          -  Progression on at least 2 prior approved systemic therapies for metastatic prostate&#xD;
             cancer (at least one must be a second-generation androgen inhibitor, e.g.,&#xD;
             abiraterone, enzalutamide, darolutamide, apalutamide).&#xD;
&#xD;
          -  Progressive mCRPC&#xD;
&#xD;
          -  Ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone&#xD;
             analog or inhibitor, or orchiectomy (surgical or medical castration).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known symptomatic brain metastases requiring steroids (above physiologic replacement&#xD;
             doses).&#xD;
&#xD;
          -  Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular&#xD;
             disease, or previous gastric resection or lap band surgery.&#xD;
&#xD;
          -  Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to&#xD;
             &gt;25% of the bone marrow.&#xD;
&#xD;
          -  Receipt of an investigational drug(s) within 4 weeks prior to anticipated first dose&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arvinas Androgen Receptor, Inc.</last_name>
    <phone>475-345-3374</phone>
    <email>clinicaltrialsARV-766@arvinas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Prostate Cancer</keyword>
  <keyword>Castrate-Resistant</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>mCRPC adenocarcinoma of prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

